Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.
about
Species differences in tumour responses to cancer chemotherapyInfluence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.Population pharmacokinetics of raltitrexed in patients with advanced solid tumoursEnzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery.Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and ChildrenMetabolism and transport of oxazaphosphorines and the clinical implications.Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.Dose-toxicity models in oncology.Benchmarking therapeutic drug monitoring software: a review of available computer tools.Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.Non-Markovian Population Dynamics: Does it Help to Optimize the Chemotherapeutic Strategy?Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.Inter occasion variability in individual optimal designDose adaptation of capecitabine based on individual prediction of limiting toxicity grade: evaluation by clinical trial simulation.Nanomedicine Faces Barriers.Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.Impact of Pretreatment Neutrophil Count on Chemotherapy Administration and Toxicity in Dogs with Lymphoma Treated with CHOP Chemotherapy.Detection of low-quantity anticancer drugs by surface-enhanced Raman scattering.Kinetic nomograms assist individualization of drug regimens.Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer.Dose calculation of anticancer drugs
P2860
Q28080727-050F1FAE-3994-4FEA-BBD0-9ED3DBA0B658Q30655795-37104A40-8FFC-4F85-9677-C2C347C6134BQ35826027-3E08AEDB-B93F-430D-A5C1-226B52968A73Q36024654-594C108E-CE1B-4EF9-BA58-92AF6F2E2993Q36322918-F2FDB0CF-8E37-4D8D-9041-CA4D394A00A4Q36360811-C73708D8-9E21-4D4D-80A1-447F78656B2DQ36788423-751042F4-CAC8-4147-BE3C-86C9E298FEE8Q37684533-F61B0850-01D5-4F25-A7BC-362CF4B7BA65Q37829437-AD80335B-C3CF-47C5-9BCC-2C243F54542EQ38063750-F7FE1C39-7E60-4AAD-BE98-8EC796B8842AQ38612229-8C557FAF-C2C5-4BBE-AB3F-142523FC5F4CQ39528378-C1189C60-C2C4-4FCD-8514-78CE2844418DQ39651800-F568CFA0-A0AF-4BC1-8B2A-B8B8EF086687Q40447879-306FA347-BD2A-41CA-954E-D255556EB139Q44002046-1C3AAF56-CFD6-4FB3-A698-5845B71ECA39Q46181824-37AEB738-4459-4760-87BD-D7C8F614EFF9Q47592832-CE4D4DF3-8D6C-41CC-B305-7531E6215EC6Q48179867-03F210AC-7123-41C3-9DE7-66E316215535Q48246143-D9D4FF95-59BA-46F0-A618-CC16F322393CQ51497219-4AA3C962-6094-4A7C-B147-6C9611CD4CF7Q51530980-4A4C6981-EA57-4060-B6D5-CBABE6EDD10EQ52576799-7E0662F8-DEF7-4E10-AA62-5AF19381C132Q56391087-082C6AA4-0331-411F-8053-0A93C9B26EAA
P2860
Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs.
description
2002 nî lūn-bûn
@nan
2002 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Application of pharmacokinetic ...... onitoring of anticancer drugs.
@ast
Application of pharmacokinetic ...... onitoring of anticancer drugs.
@en
type
label
Application of pharmacokinetic ...... onitoring of anticancer drugs.
@ast
Application of pharmacokinetic ...... onitoring of anticancer drugs.
@en
prefLabel
Application of pharmacokinetic ...... onitoring of anticancer drugs.
@ast
Application of pharmacokinetic ...... onitoring of anticancer drugs.
@en
P2860
P1476
Application of pharmacokinetic ...... onitoring of anticancer drugs.
@en
P2093
Annick Rousseau
P2860
P304
P356
10.1046/J.1472-8206.2002.00086.X
P577
2002-08-01T00:00:00Z